Roche Labs update insert for saquinavir
Roche Labs update insert for saquinavir
Roche Laboratories, Inc. has updated their package insert for their protease inhibitor, saquinavir (Invirase) to include the following drug interaction information and include new warnings regarding coadministration of saquinavir/ritonavir and digoxin (used in the treatment of various cardiac conditions).
Updated drug interaction information has been added on five products in the product package insert revision:
- Digoxin: A new warning has been added. Caution should be exercised when Invirase and digoxin are coadministered. Coadministration results in a significant increase in serum concentration of digoxin; therefore, the serum concentration of digoxin should be monitored and the dose of digoxin may need to be reduced.
- Garlic capsules: No data are available for the coadministration of saquinavir/ritonavir with garlic capsules. A warning has been added that the coadministration of garlic capsules and saquinavir is not recommended due to the potential for garlic capsules to induce the metabolism of saquinavir, which may result in subtherapeutic saquinavir concentrations.
- Methadone: Methadone levels are decreased and the dosage of methadone may need to be increased when coadministered with saquinavir/ritonavir.
- Tipranavir/ritonavir: Combining saquinavir with tipranavir/ritonavir is not recommended due to a decrease in saquinavir levels with coadministration.
- Omeprazole: When Invirase/ritonavir is coadministered with omeprazole, saquinavir concentrations are increased significantly. If omeprazole or another proton pump inhibitor is taken concomitantly with Invirase/ritonavir, caution is advised and monitoring for potential saquinavir toxicities is recommended, particularly gastrointestinal symptoms, increased triglycerides, and deep vein thrombosis.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.